drugset / Trial / NCT00697242

Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults

NCT00697242

Phase 3 Completed 362 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindPrevention

Summary

In the present study the immunogenicity, reactogenicity and safety of recombinant hepatitis B vaccines with and without MPL will be evaluated in older healthy subjects

Timeline

Start
1994-01
Primary completion
1995-11
Completion
1995-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Engerix-B Vaccine Intramuscular
Subject Recombinant HBsAg Vaccine Intramuscular